Greater clarity is needed on multiple aspects of the US Food and Drug Administration’s latest draft guidance on competitive generic therapies, according to comments submitted by several generics firms and industry representatives.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?